ReCor appoints Lara Barghout to lead commercialisation of Paradise renal denervation system

1496
Lara Barghout

ReCor Medical and its parent company Otsuka Medical Devices have announced the appointment of Lara Barghout as president and chief executive officer of ReCor.

Barghout will lead the ReCor business strategy and organisation in the global commercialisation of ReCor’s Paradise ultrasound renal denervation system for the treatment of hypertension. She brings more than 20 years of experience leading global businesses in the medical device industry, joining ReCor from Siemens Healthineers, where she was senior vice president and head of advanced therapies, leading the image guided therapy business in North America. Prior to Siemens Healthineers, Barghout held several roles at Terumo Cardiovascular.

“I am honoured to lead the extraordinary team at ReCor at an exciting time in the company’s growth,” said Barghout. “High blood pressure is a leading contributor to cardiovascular disease burden worldwide, resulting in increased patient risk and higher costs to health systems. I look forward to leading our focus to advance ultrasound renal denervation as a treatment for hypertension and the global commercialisation of the Paradise ultrasound renal denervation system. We believe our Paradise ultrasound renal denervation technology to be a true game changer in improving hypertension therapy, with the potential to offer a new option for physicians to help improve blood pressure outcomes for their patients on a global scale.”

Barghout succeeds Andrew Weiss, who joined ReCor in 2013 and led ReCor in the development of the Paradise system from its early clinical trials, to the acquisition of ReCor by Otsuka in 2018, through the RADIANCE trial successes and the recent submission to the US Food and Drug Administration (FDA) for premarket approval.

“We are delighted to name Ms Barghout President and CEO of ReCor. She is a highly experienced leader with a track record of commercial success across a range of medical device businesses, coupled with extensive experience in global leadership,” said Noriko Tojo, executive director of Otsuka Holdings and president of Otsuka Medical Devices. “We are very excited for Ms Barghout to lead ReCor into its next phase of global growth. Her deep commercial experience and adept leadership make her ideal to build on the technology development and clinical trial successes of the ReCor team, guiding the business to realise its therapeutic and commercial potential. I would like to thank Andy for his outstanding leadership and countless contributions over the past 10 years.”

The Paradise system bears the CE mark for the treatment of hypertension in Europe and is an investigational device in the USA and Japan.


LEAVE A REPLY

Please enter your comment!
Please enter your name here